Thermal Management in Patients With Interventional Minimally Invasive Valve Replacement (TIMI)
This study has been completed.
Sponsor:
Charite University, Berlin, Germany
Information provided by:
Charite University, Berlin, Germany
ClinicalTrials.gov Identifier:
NCT01176110
First received: July 29, 2010
Last updated: May 18, 2011
Last verified: July 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
It is known that perioperative hypothermia can influence the postoperative outcome negatively.
The most important complications are cardiac, increased blood loss with need for transfusion and a significantly increased wound infection rate.
The thermal redistribution after the induction of anesthesia is on of the reasons for perioperative hypothermia. Another reason is negative heat balance during surgery.
Further negative side effects of hypothermia are an increase of blood viscosity and thus a higher risk for thrombosis, coagulopathy and thus an increased risk of bleeding.
The aim of the study is to evaluate if patients with a perioperative active thermal management during an interventional minimal invasive valve replacement have a significantly higher body temperature at the end of the operation than patients without an active thermal management. Secondary outcome variables are complication rates, length of mechanical ventilation and length of ICU treatment.
| Condition | Intervention |
|---|---|
|
Outcomes Body Temperature |
Device: LMA Perfect Temp |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Supportive Care |
| Official Title: | A Randomized Pilot Study for Thermal Management in Patients With Interventional Minimally Invasive Valve Replacement |
Resource links provided by NLM:
Further study details as provided by Charite University, Berlin, Germany:
Primary Outcome Measures:
- Temperature at the end of the intervention [ Time Frame: average 2 hours ] [ Designated as safety issue: Yes ]The end of the surgical procedure is defined and is recorded for all patients in the hospital information systems. This time point will be used to record the body temperature at the end of the intervention
Secondary Outcome Measures:
- hospital stay [ Time Frame: max 28 days ] [ Designated as safety issue: No ]
- mechanical ventilation time [ Time Frame: maximum 28 days ] [ Designated as safety issue: No ]The mechanical ventilation time in the hospital is recorded electronically. The time frame will be recorded as the outcome measure in this study.
| Estimated Enrollment: | 40 |
| Study Start Date: | July 2010 |
| Study Completion Date: | May 2011 |
| Primary Completion Date: | March 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: thermal management with LMA PerfecTemp™ |
Device: LMA Perfect Temp
The LMA PerfecTemp™ patient warming system combines warming beneath the patient and advanced pressure reduction to combat hypothermia and decubitus ulcers. This device is used during the interventional minimal invasive valve replacement with unprecedented ease and safety
|
| Active Comparator: no specific thermal management |
Device: LMA Perfect Temp
The LMA PerfecTemp™ patient warming system combines warming beneath the patient and advanced pressure reduction to combat hypothermia and decubitus ulcers. This device is used during the interventional minimal invasive valve replacement with unprecedented ease and safety
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients, who need an interventional minimal invasive valve replacement
- Age ≥ 18 years
- scheduled general anesthesia during intervention
- no participation on another interventional study
- signed informed consent
Exclusion Criteria:
- pregnant or breast feeding women
- non-elective intervention
- conversion to HLM
- implantation of IABP
- pre-existing decubitus
- patients who are not able to sign informed consent
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01176110
Locations
| Germany | |
| Department of Anesthesiology and Intensive Care Medicine Campus Charité Mitte / Campus Virchow-Klinikum | |
| Berlin, Germany, 10117 | |
Sponsors and Collaborators
Charite University, Berlin, Germany
Investigators
| Principal Investigator: | Michael Sander, MD | Dept. of Anesthesiology Charité Universitaetsmedizin Berlin |
| Study Chair: | Claudia Spies, MD | Dept. of Anesthesiology Charité Universitaetsmedizin Berlin |
More Information
No publications provided
| Responsible Party: | PD Dr. Michael Sander, Department of Anesthesiology and Intensive Care Medicine Campus Charité Mitte / Campus Virchow-Klinikum Charité - Universitätsmedizin Berlin |
| ClinicalTrials.gov Identifier: | NCT01176110 History of Changes |
| Other Study ID Numbers: | TIMI101, EA1/142/10 |
| Study First Received: | July 29, 2010 |
| Last Updated: | May 18, 2011 |
| Health Authority: | Germany: Ethics Commission |
Keywords provided by Charite University, Berlin, Germany:
|
hypothermia minimal invasive valve replacement |
ClinicalTrials.gov processed this record on May 23, 2013